Full Text View
Tabular View
No Study Results Posted
Related Studies
Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
This study has been completed.
Study NCT00076011   Information provided by Pfizer
First Received: January 12, 2004   Last Updated: August 14, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Neoplasms
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
VEGFR and PDGFR inhibitor
Additional drug interventions recognized in this trial
Angiogenesis Inhibitors
More general drug interventions related to this trial
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services